The latest update is out from PepGen Inc. ( (PEPG) ).
On February 24, 2025, PepGen Inc. announced positive initial results from its ongoing FREEDOM-DM1 trial for patients with myotonic dystrophy type 1 (DM1), showing significant splicing correction in different dosage cohorts. The company also reported its financial results for the fourth quarter and year-end 2024, highlighting increased research and development expenses and a net loss, yet maintaining a strong cash position to fund operations into 2026. These developments underscore PepGen’s commitment to advancing its therapeutic candidates and its strategic positioning in the biotechnology industry.
More about PepGen Inc.
PepGen is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. The company’s proprietary EDO platform leverages cell-penetrating peptides to enhance the uptake and efficacy of oligonucleotide therapeutics, targeting the root causes of these conditions.
YTD Price Performance: -63.66%
Average Trading Volume: 320,378
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.66M
See more insights into PEPG stock on TipRanks’ Stock Analysis page.